The relatively short time for which the disease has been recognised coupled with its rare nature means the disease has lacked standard diagnosis and treatment protocols until very recently. This, together with the fact that the disease affects people of all ages and is of relapse-remitting type means the registry data are highly heterogeneous. We used advancing processing techniques to extract actionable insights from these heterogeneous data. This week, these insights were presented to our client who produce a leading treatment. They'll use these insights to inform their market access strategy. The analyses have revealed key areas in which their drug offers competitive advantage over other treatments, including benefits of which they were previously unaware. The analyses have delivered concrete statistics to back up anecdotal benefits. This work is expected to deliver a step-change in future management, moving towards a personalised medicine approach to selecting treatment for optimal patient outcomes. ​